These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 32855207)

  • 21. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
    Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
    Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and application of 131I-fulvestrant as a targeted radiation drug for endocrine therapy in human breast cancer.
    Yin G; Zeng B; Peng Z; Liu Y; Sun L; Liu C
    Oncol Rep; 2018 Mar; 39(3):1215-1226. PubMed ID: 29328488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
    Garvin S; Dabrosin C
    Cancer Res; 2003 Dec; 63(24):8742-8. PubMed ID: 14695189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.
    Osborne CK; Coronado-Heinsohn EB; Hilsenbeck SG; McCue BL; Wakeling AE; McClelland RA; Manning DL; Nicholson RI
    J Natl Cancer Inst; 1995 May; 87(10):746-50. PubMed ID: 7563152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ; Johnston SR; Howell A
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
    Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
    Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
    Guan J; Zhou W; Hafner M; Blake RA; Chalouni C; Chen IP; De Bruyn T; Giltnane JM; Hartman SJ; Heidersbach A; Houtman R; Ingalla E; Kategaya L; Kleinheinz T; Li J; Martin SE; Modrusan Z; Nannini M; Oeh J; Ubhayakar S; Wang X; Wertz IE; Young A; Yu M; Sampath D; Hager JH; Friedman LS; Daemen A; Metcalfe C
    Cell; 2019 Aug; 178(4):949-963.e18. PubMed ID: 31353221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
    Journé F; Body JJ; Leclercq G; Laurent G
    Expert Opin Drug Saf; 2008 May; 7(3):241-58. PubMed ID: 18462183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells.
    Nukatsuka M; Saito H; Noguchi S; Takechi T
    In Vivo; 2019; 33(5):1439-1445. PubMed ID: 31471390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activating
    Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
    Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination.
    Parisian AD; Barratt SA; Hodges-Gallagher L; Ortega FE; Peña G; Sapugay J; Robello B; Sun R; Kulp D; Palanisamy GS; Myles DC; Kushner PJ; Harmon CL
    Mol Cancer Ther; 2024 Mar; 23(3):285-300. PubMed ID: 38102750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.
    Kaminska K; Akrap N; Staaf J; Alves CL; Ehinger A; Ebbesson A; Hedenfalk I; Beumers L; Veerla S; Harbst K; Ehmsen S; Borgquist S; Borg Å; Pérez-Fidalgo A; Ditzel HJ; Bosch A; Honeth G
    Breast Cancer Res; 2021 Feb; 23(1):26. PubMed ID: 33602273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.